Americas
Worldwide
Japan
Asia Pacific
Americas
Europe, Middle East, and Africa
Mizuho Bank
Mizuho Trust & Banking
Mizuho Securities
Mizuho Research & Technologies
Search
Who We Are
Our People
Diversity & Inclusion
Awards
Locations
Events
What We Do
Banking
Overview
Industry Coverage
Consumer + Retail
Energy
Financial Institutions
Financial Sponsors
Healthcare
Industrials
Power + Utilities + Infrastructure
Real Estate
Technology + Media + Telecom
Corporate Banking
Debt Capital Markets
Equity Capital Markets
Leveraged Finance
Mergers & Acquisitions
Private Capital Advisory
Mizuho | Greenhill International Presence
Regional Coverage
Restructuring
Risk Solutions
Banking Insights
Markets
Overview
Equities
Fixed Income
Futures + Options
Research
Overview
Corporate & Institutional Services
Overview
Treasury Services
Overview
Commercial Card
Deposits
Cash Management
Insights + News
Insights
News
Press Releases
Sustainability
Sustainability
Community
Foundation
Media Relations
Press Releases-
Media Contacts & Resources-
Careers
Client Login
Futures-
US Equity Research-
Japan Equity Research-
Global Custody-
Commercial Card Portal-
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho’s Jared Holz
January 24, 2025
Jared Holz, Mizuho, joins ‘Fast Money’ to talk Novo Nordisk’s recent climb.
Share This
Latest Mizuho News
See all news
Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz
February 17, 2026
Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz
February 23, 2026
Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev
February 25, 2026
Mizuho news from around the globe
Mizuho Global News
back-to-top-blue
